Our CEO, Geoff Hale, has been confirmed as a keynote speaker at Antibody Engineering and Therapeutics 2023 in Amsterdam. Geoff will be talking about the diversity of antibody formats and modiciations utilised in the clinic and in particular focussing on Fc silencing and the work mAbsolve has done to compare it’s STR silencing mutations with other reported approaches to reduce antibody effector function.

Posted in